13/02/2018 15:47:00

Alder BioPharmaceuticals, Inc. Announces Exercise in Full of Underwriters’ Option to Purchase Additional 2.50% Convertible Senior Notes Due 2025

BOTHELL, Wash., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that the underwriters of its previously announced offering of 2.50% convertible senior notes due 2025 (the “Notes”) have exercised in full their option to purchase up to an additional $37.5 million aggregate principal amount of Notes, solely to cover over-allotments, for a total offering of $287.5 million in aggregate principal amount. The sale of additional Notes closed on February 13, 2018.

Alder intends to use net proceeds from the offering to fund the development and commercialization of eptinezumab, and in particular, activities in support of achieving approval by the U.S. Food and Drug Administration for, and executing the commercial launch of, the infusion formulation of eptinezumab.

Goldman Sachs & Co. LLC, Leerink Partners LLC and Wells Fargo Securities, LLC acted as book-running managers for the offering.

A shelf registration statement relating to the offering was filed with the Securities and Exchange Commission (the “SEC”), and was effective on filing on February 23, 2017.  A final prospectus supplement and the accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone toll-free at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate, 375 Park Avenue, New York, New York 10152, by telephone toll-free at 800-326-5897 or by email at cmclientsupport@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Alder’s anticipated use of net proceeds from the offering, and the continued development and commercialization of eptinezumab. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Alder is contained in the section captioned "Risk Factors" in the final prospectus supplement related to the public offering filed with the SEC and other filings with the SEC from time to time. Alder disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Ashley Cadle

TogoRun

310-463-0143

a.cadle@togorun.com

 

Investor Relations Contact:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker mine analyse af Pandoras forretnings..
81
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
31
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
30
15:05
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
28
13 Feb
 
Lad dog Henrik dø i fred i stedet for at komme med jeres dumsmarte bemærkninger   Det er upazsende u..
28
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
20
15 Feb
OMXC20
Kære alle. Jeg har flere gange tilbudt at svare på investeringsspørgsmål for at bidrage til at så ma..
20
17 Feb
E:QEC
Med fare for en gentagelse, så vil jeg alligevel melde at Canada er i fuld gang med at omstille sig ..
18
13 Feb
 
nu syntes jeg i er for åndsvage manden er ved at dø forhelvede
18
17 Feb
MAERSK-B
Jeg er i mit vemodige hjørne i dag, for det er den første dag i over 25 år, hvor jeg ikke kan kalde ..
17

Elliott Capital Advisors, L.P : Form 8.3 - Melrose Industries Plc

19/02/2018 15:25:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Alliance Trust PLC : Net Asset Value(s)

19/02/2018 13:15:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 16 February 2018: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 774.6p -       including income, 779.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Invesco Ltd. : Form 8.3 - Tesco Plc

19/02/2018 10:53:43
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Invesco Ltd. (b) Owner or control..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
2
BEST Background Check Site Comparison Announced by Background Check Solutions
3
RCI Banque : 2017, ANOTHER YEAR OF STRONG GROWTH: NEW FINANCINGS OF €20.6 BILLION AND PRE-TAX INCOME OF €1,077 MILLION.
4
Bone Therapeutics SA completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®
5
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Key Technology, Inc.

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 February 2018 21:42:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180219.1 - EUROWEB6 - 2018-02-19 22:42:04 - 2018-02-19 21:42:04 - 1000 - Website: OKAY